Anaptysbio (ANAB) EBITDA Margin Growth (1y) (2017 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) EBITDA Margin Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -1,651.00 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 29,091.00 |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -3,637.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -3,637.00 |
| Dec 31, 2025 | 12,788.00 |
| Sep 30, 2025 | 12,129.00 |
| Jun 30, 2025 | 24,997.00 |
| Mar 31, 2025 | 48,867.00 |
| Dec 31, 2024 | 42,923.00 |
| Sep 30, 2024 | 106,138.00 |
| Jun 30, 2024 | 79,268.00 |
| Mar 31, 2024 | 264,367.00 |
| Dec 31, 2023 | 5,155.00 |
| Sep 30, 2023 | 115,461.00 |
| Jun 30, 2023 | 112,590.00 |
| Mar 31, 2023 | 4,158.00 |
| Dec 31, 2022 | 256,234.00 |
| Sep 30, 2022 | -225,943.00 |
| Jun 30, 2022 | -228,433.00 |
| Mar 31, 2022 | -310,984.00 |
| Dec 31, 2021 | -313,738.00 |
| Mar 31, 2021 | -9,490.00 |
| Dec 31, 2020 | 79,751.00 |